美国食品药品监督管理局通知。马拉维若被批准为一种CCR5共受体拮抗剂。 - Suppr

Suppr

超能文献

FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.

出版信息

AIDS Alert. 2007 Sep;22(9):103.

PMID:18411462

Abstract

摘要

相似文献

FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.

AIDS Alert. 2007 Sep;22(9):103.

Something new under the sun. Maraviroc poised for approval.

GMHC Treat Issues. 2006 Aug-Dec;20(8-12):1-4.

FDA advisory committee approves Selzentry.

AIDS Patient Care STDS. 2009 Nov;23(11):987.

Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.

AIDS Alert. 2009 Jan;24(1):10-2.

FDA panel backs HIV drug.

AIDS Read. 2007 Jun;17(6):294.

An in-depth look at the challenges of prescribing maraviroc.

HIV Clin. 2008 Summer;20(3):9-11.

Drug safety evaluation of maraviroc for the treatment of HIV infection.

Expert Opin Drug Saf. 2012 Jan;11(1):161-74. doi: 10.1517/14740338.2012.640670. Epub 2011 Nov 26.

FDA approves maraviroc tablets.

AIDS Patient Care STDS. 2007 Sep;21(9):702. doi: 10.1089/apc.2007.9970.

Treatment of HIV infection with the CCR5 antagonist maraviroc.

Expert Opin Pharmacother. 2010 May;11(7):1215-23. doi: 10.1517/14656561003801081.

Maraviroc: integration of a new antiretroviral drug class into clinical practice.

J Antimicrob Chemother. 2008 Jun;61(6):1187-90. doi: 10.1093/jac/dkn130. Epub 2008 Apr 9.

引用本文的文献

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.

bioRxiv. 2024 Feb 12:2023.11.15.567150. doi: 10.1101/2023.11.15.567150.

CCR5 Inhibitors and HIV-1 Infection.

J AIDS HIV Treat. 2019;1(1):1-5. doi: 10.33696/AIDS.1.001.

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5.

Acta Pharmacol Sin. 2019 Apr;40(4):563-568. doi: 10.1038/s41401-018-0054-2. Epub 2018 Jun 25.

Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Pharmacol Res Perspect. 2016 Oct 18;4(6):e00262. doi: 10.1002/prp2.262. eCollection 2016 Dec.

The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.

PLoS One. 2015 Jul 8;10(7):e0131894. doi: 10.1371/journal.pone.0131894. eCollection 2015.

Targeting CCR5 for anti-HIV research.

Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1881-7. doi: 10.1007/s10096-014-2173-0. Epub 2014 Jun 11.

Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

Science. 2013 Sep 20;341(6152):1387-90. doi: 10.1126/science.1241475. Epub 2013 Sep 12.

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.

Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Virol J. 2009 Nov 18;6:201. doi: 10.1186/1743-422X-6-201.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验